Molecular imaging to identify the vulnerable plaque-from basic research to clinical practice

Molecular Imaging and Biology

Volumn 14, Issue 5, 2012, Pages 523-533

  Kusters, Dennis H M ^a   Tegtmeier, Jan ^a   Schurgers, Leon J ^a   Reutelingsperger, Chris P M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Molecular imaging; MRI; PET; Vulnerable plaque

Indexed keywords

OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BASIC RESEARCH; BLOOD VESSEL CALCIFICATION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; HUMAN; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; SOCIOECONOMICS; THROMBOSIS; VASCULITIS;

CELL DEATH; HUMANS; INFLAMMATION; MOLECULAR IMAGING; PLAQUE, ATHEROSCLEROTIC; SOCIOECONOMIC FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84870396285     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0586-7     Document Type: Review

References (132)

1. Borissoff JI, Spronk HM, ten Cate H (2011) The hemostatic system as a modulator of atherosclerosis. N Engl J Med 364(18):1746-1760
2. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340(2):115-126
3. Libby P (1995) Molecular bases of the acute coronary syndromes. Circulation 91(11):2844-2850
4. Virmani R, Burke AP, Kolodgie FD et al (2002) Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 15(6):439-446
5. Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347):317-325
6. Libby P, Sukhova G, Lee RT et al (1995) Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 25(Suppl 2):S9-S12
7. Tzoulaki I, Liberopoulos G, Ioannidis JP (2009) Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 302 (21):2345-2352
8. Davies MJ (1990) A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 82(3 Suppl):II38-II46
9. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685-1695
10. Wang TJ, Gona P, Larson MG et al (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355(25):2631-2639
11. Matter CM, Stuber M, Nahrendorf M (2009) Imaging of the unstable plaque: how far have we got? Eur Heart J 30(21):2566-2574
12. Yuan C, Hatsukami TS, Cai J (2005) MRI plaque tissue characterization and assessment of plaque stability. Stud Health Technol Inform 113:55-74
13. Bouki KP, Katsafados MG, Chatzopoulos DN et al (2012) Inflammatory markers and plaque morphology: an optical coherence tomography study. Int J Cardiol 154(3):287-292
14. Kerwin WS, O'Brien KD, Ferguson MS et al (2006) Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology 241(2):459-468
15. Tabas I (2010) Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 10(1):36-46
16. Gao T, Zhang Z, Yu W et al (2009) Atherosclerotic carotid vulnerable plaque and subsequent stroke: a high-resolution MRI study. Cerebrovasc Dis 27(4):345-352
17. Kolodgie FD, Narula J, Haider N et al (2001) Apoptosis in atherosclerosis. Does it contribute to plaque instability? Cardiol Clin 19(1):127-139, ix
18. Tabas I (2011) Pulling down the plug on atherosclerosis: finding the culprit in your heart. Nat Med 17(7):791-793
19. Derksen WJ, Peeters W, van Lammeren GW et al (2011) Different stages of intraplaque hemorrhage are associated with different plaque phenotypes: a large histopathological study in 794 carotid and 276 femoral endarterectomy specimens. Atherosclerosis 218(2):369-377
20. Bazeli R, Coutard M, Duport BD et al (2010) In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol 45(10):662-668
21. Galis ZS, Sukhova GK, Lark MW et al (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94(6):2493-2503
22. Johnson JL, George SJ, Newby AC et al (2005) Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A 102(43):15575-15580
23. Lancelot E, Amirbekian V, Brigger I et al (2008) Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol 28(3):425-432
24. Loftus IM, Naylor AR, Bell PR et al (2002) Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 89(6):680-694
25. Ouimet T, Lancelot E, Hyafil F et al (2012) Molecular and cellular targets of the MRI contrast agent p947 for atherosclerosis imaging. Mol Pharm 9(4):850-861
26. Winter PM, Morawski AM, Caruthers SD et al (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrintargeted nanoparticles. Circulation 108(18):2270-2274
27. Vengrenyuk Y, Cardoso L, Weinbaum S (2008) Micro-CT based analysis of a new paradigm for vulnerable plaque rupture: cellular microcalcifications in fibrous caps. Mol Cell Biomech 5(1):37-47
28. Vengrenyuk Y, Carlier S, Xanthos S et al (2006) A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci U S A 103(40):14678-14683
29. Slager CJ, Wentzel JJ, Gijsen FJ et al (2005) The role of shear stress in the generation of rupture-prone vulnerable plaques. Nat Clin Pract Cardiovasc Med 2(8):401-407
30. Bennett MR (2010) Life and death in the atherosclerotic plaque. Curr Opin Lipidol 21(5):422-426
31. Van Vre EA, Ait-Oufella H, Tedgui A et al (2012) Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 32(4):887-893
32. Thorp E, Tabas I (2009) Mechanisms and consequences of efferocytosis in advanced atherosclerosis. J Leukoc Biol 86(5):1089-1095
33. Tabas I (2009) Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. Antioxid Redox Signal 11(9):2333-2339
34. Schrijvers DM, De Meyer GR, Kockx MM et al (2005) Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 25(6):1256-1261
35. Schoenenberger AW, Urbanek N, Bergner M et al (2012) Associations of reactive hyperemia index and intravascular ultrasound-assessed coronary plaque morphology in patients with coronary artery disease. Am J Cardiol 109(12):1711-1716
36. Moore KJ, Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145(3):341-355
37. Visioni A, Kim J (2011) Positron emission tomography for benign and malignant disease. Surg Clin North Am 91(1):249-266
38. Yun M, Yeh D, Araujo LI et al (2001) F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 26(4):314-319
39. Rudd JH, Myers KS, Bansilal S et al (2007) (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol 50(9):892-896
40. Rudd JH, Myers KS, Bansilal S et al (2009) Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2 (2):107-115
41. Tawakol A, Migrino RQ, Bashian GG et al (2006) In vivo 18 Ffluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48(9):1818-1824
42. Laufer EM, Winkens HM, Corsten MF et al (2009) PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled Annexin A5. Q J Nucl Med Mol Imaging 53(1):26-34
43. Paulmier B, Duet M, Khayat R et al (2008) Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol 15 (2):209-217
44. Goyal T, Mitra S, Khaidakov M et al (2012) Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr Atheroscler Rep 14(2):150-159
45. Reiss AB, Anwar K, Wirkowski P (2009) Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) in atherogenesis: a brief review. Curr Med Chem 16(21):2641-2652
46. Ishino S, Mukai T, Kuge Y et al (2008) Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti- LOX-1 antibody: potential agent for imaging of vulnerable plaque. J Nucl Med 49(10):1677-1685
47. Li D, Patel AR, Klibanov AL et al (2010) Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging 3 (4):464-472
48. Canat X, Guillaumont A, Bouaboula M et al (1993) Peripheral benzodiazepine receptor modulation with phagocyte differentiation. Biochem Pharmacol 46(3):551-554
49. Chen W, Cormode DP, Fayad ZA et al (2010) Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3(2):146- 161
50. Sadeghi MM, Glover DK, Lanza GM et al (2010) Imaging atherosclerosis and vulnerable plaque. J Nucl Med 51(Suppl 1):51S-65S
51. Schmitz SA, Coupland SE, Gust R et al (2000) Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 35(8):460-471
52. Sanz J, Fayad ZA (2008) Imaging of atherosclerotic cardiovascular disease. Nature 451(7181):953-957
53. Trivedi RA, Mallawarachi C, U-King-Im JM et al (2006) Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 26(7):1601- 1606
54. Amirbekian V, Aguinaldo JG, Amirbekian S et al (2009) Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology 251(2):429-438
55. Frias JC, Williams KJ, Fisher EA et al (2004) Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 126(50):16316-16317
56. Kooi ME, Cappendijk VC, Cleutjens KB et al (2003) Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107(19):2453-2458
57. Lipinski MJ, Frias JC, Amirbekian V et al (2009) Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging 2(5):637-647
58. Blann AD, Nadar SK, Lip GY (2003) The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 24(24):2166-2179
59. Rouzet F, Bachelet-Violette L, Alsac JM et al (2011) Radiolabeled fucoidan as a p-selectin targeting agent for in vivo imaging of plateletrich thrombus and endothelial activation. J Nucl Med 52(9):1433-1440
60. Jacobin-Valat MJ, Deramchia K, Mornet S et al (2010) MRI of inducible p-selectin expression in human activated platelets involved in the early stages of atherosclerosis. NMR Biomed 24(4):413-424
61. McAteer MA, Schneider JE, Ali ZA et al (2008) Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol 28(1):77-83
62. Burtea C, Ballet S, Laurent S et al (2012) Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosistargeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol 32(6):e36-e48
63. Burtea C, Laurent S, Murariu O et al (2008) Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res 78(1):148-157
64. Rudd JH, Narula J, Strauss HW et al (2010) Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol 55(23):2527- 2535
65. Menezes LJ, Kotze CW, Hutton BF et al (2009) Vascular inflammation imaging with 18 F-FDG PET/CT: when to image? J Nucl Med 50 (6):854-857
66. Menezes LJ, Kotze CW, Agu O et al (2011) Investigating vulnerable atheroma using combined (18)F-FDG PET/CT angiography of carotid plaque with immunohistochemical validation. J Nucl Med 52(11):1698- 1703
67. Myers KS, Rudd JH, Hailman EP et al (2012) Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. JACC Cardiovasc Imaging 5(1):38-45
68. Fayad ZA, Mani V, Woodward M et al (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378(9802):1547-1559
69. Fayad ZA, Mani V, Woodward M et al (2011) Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am Heart J 162(2):214-221, e2
70. Wykrzykowska J, Lehman S, Williams G et al (2009) Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a lowcarbohydrate, high-fat preparation. J Nucl Med 50(4):563-568
71. Debruyne JC, Versijpt J, Van Laere KJ et al (2003) PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 10(3):257-264
72. Pugliese F, Gaemperli O, Kinderlerer AR et al (2010) Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography. J Am Coll Cardiol 56(8):653-661
73. Gaemperli, O., J. Shalhoub, D.R. Owen, et al. (2012) Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J (in press)
74. Kopka K, Faust A, Keul P et al (2006) 5-Pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis. J Med Chem 49(23):6704-6715
75. Chen DL, Zhou D, Chu W et al (2012) Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas antibody. Nucl Med Biol 39 (1):137-144
76. Zhou D, Chu W, Rothfuss J et al (2006) Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett 16(19):5041-5046
77. Nguyen QD, Smith G, Glaser M et al (2009) Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A 106(38):16375-16380
78. Schutters K, Reutelingsperger C (2010) Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis 15(9):1072-1082
79. Taki J, Higuchi T, Kawashima A et al (2004) Detection of cardiomyocyte death in a rat model of ischemia and reperfusion using 99mTclabeled annexin V. J Nucl Med 45(9):1536-1541
80. Takei T, Kuge Y, Zhao S et al (2005) Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation. J Nucl Med 46(5):794-799
81. Belhocine T, Steinmetz N, Hustinx R et al (2002) Increased uptake of the apoptosis-imaging agent (99 m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 8(9):2766-2774
82. Blankenberg FG, Katsikis PD, Tait JF et al (1998) In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A 95(11):6349-6354
83. Dumont EA, Reutelingsperger CP, Smits JF et al (2001) Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 7(12):1352-1355
84. Hofstra L, Liem IH, Dumont EA et al (2000) Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356 (9225):209-212
85. Kolodgie FD, Petrov A, Virmani R et al (2003) Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation 108(25):3134-3139
86. Laufer EM, Reutelingsperger CP, Narula J et al (2008) Annexin A5: an imaging biomarker of cardiovascular risk. Basic Res Cardiol 103(2):95- 104
87. Falborg L, Waehrens LN, Alsner J et al (2010) Biodistribution of 99mTc-HYNIC-lactadherin in mice-a potential tracer for visualizing apoptosis in vivo. Scand J Clin Lab Invest 70(3):209-216
88. Davletov BA, Sudhof TC (1993) A single C2 domain from synaptotagmin I is sufficient for high affinity Ca2+/phospholipid binding. J Biol Chem 268(35):26386-26390
89. Krishnan AS, Neves AA, de Backer MM et al (2008) Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology 246(3):854-862
90. Alam IS, Neves AA, Witney TH et al (2010) Comparison of the C2A domain of synaptotagmin-I and annexin-V as probes for detecting cell death. Bioconjug Chem 21(5):884-891
91. Kietselaer BL, Reutelingsperger CP, Heidendal GA et al (2004) Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 350(14):1472-1473
92. Takeuchi H, Morino Y, Matsukage T et al (2009) Impact of vascular remodeling on the coronary plaque compositions: an investigation with in vivo tissue characterization using integrated backscatter-intravascular ultrasound. Atherosclerosis 202(2):476-482
93. Pasterkamp G, Fitzgerald PF, de Kleijn DP (2002) Atherosclerotic expansive remodeled plaques: a wolf in sheep's clothing. J Vasc Res 39 (6):514-523
94. Iyemere VP, Proudfoot D, Weissberg PL et al (2006) Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med 260(3):192-210
95. Shanahan CM, Weissberg PL (1999) Smooth muscle cell phenotypes in atherosclerotic lesions. Curr Opin Lipidol 10(6):507-513
96. Carrio I, Pieri PL, Narula J et al (1998) Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. J Nucl Cardiol 5(6):551-557
97. Narula J, Petrov A, Bianchi C et al (1995) Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab′)2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments. Circulation 92(3):474-484
98. Narula J, Petrov A, Pak KY et al (1997) Noninvasive detection of atherosclerotic lesions by 99mTc-based immunoscintigraphic targeting of proliferating smooth muscle cells. Chest 111(6):1684-1690
99. Tekabe Y, Einstein AJ, Johnson LL et al (2010) Targeting very small model lesions pretargeted with bispecific antibody with 99mTc-labeled high-specific radioactivity polymers. Nucl Med Commun 31(4):320- 327
100. Jimenez J, Donahay T, Schofield L et al (2005) Smooth muscle cell proliferation index correlates with 111In-labeled antibody Z2D3 uptake in a transplant vasculopathy swine model. J Nucl Med 46 (3):514-519
101. Johnson LL, Schofield LM, Verdesca SA et al (2000) In vivo uptake of radiolabeled antibody to proliferating smooth muscle cells in a swine model of coronary stent restenosis. J Nucl Med 41(9):1535-1540
102. Hyafil F, Vucic E, Cornily JC et al (2011) Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. Eur Heart J 32(12):1561-1571
103. Deguchi JO, Aikawa M, Tung CH et al (2006) Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 114(1):55-62
104. Ohshima S, Petrov A, Fujimoto S et al (2009) Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein e or low-density-lipoprotein receptor. J Nucl Med 50(4):612-617
105. ten Kate GL, Sijbrands EJ, Valkema R et al (2010) Molecular imaging of inflammation and intraplaque vasa vasorum: a step forward to identification of vulnerable plaques? J Nucl Cardiol 17(5):897-912
106. Moulton KS (2006) Angiogenesis in atherosclerosis: gathering evidence beyond speculation. Curr Opin Lipidol 17(5):548-555
107. Matter CM, Schuler PK, Alessi P et al (2004) Molecular imaging of atherosclerotic plaques using a human antibody against the extradomain B of fibronectin. Circ Res 95(12):1225-1233
108. Cai W, Chen K, Mohamedali KA et al (2006) PET of vascular endothelial growth factor receptor expression. J Nucl Med 47 (12):2048-2056
109. Rodriguez-Porcel M (2009) Non-invasive monitoring of angiogenesis in cardiology. Curr Cardiovasc Imaging Rep 2(1):59-66
110. Clofent-Sanchez G, Jacobin-Valat MJ, Laroche-Traineau J (2012) The growing interest of fibrin imaging in atherosclerosis. Atherosclerosis 222(1):22-25
111. Tavora F, Cresswell N, Li L et al (2010) Immunolocalisation of fibrin in coronary atherosclerosis: implications for necrotic core development. Pathology 42(1):15-22
112. Sato Y, Hatakeyama K, Yamashita A et al (2005) Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. Heart 91(4):526-530
113. Botnar RM, Buecker A, Wiethoff AJ et al (2004) In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 110 (11):1463-1466
114. Spuentrup E, Buecker A, Katoh M et al (2005) Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 111(11):1377-1382
115. Spuentrup E, Botnar RM, Wiethoff AJ et al (2008) MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol 18(9):1995-2005
116. Spuentrup E, Katoh M, Buecker A et al (2007) Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol 42(8):586-595
117. Makowski MR, Forbes SC, Blume U et al (2012) In vivo assessment of intraplaque and endothelial fibrin in ApoE(-/-) mice by molecular MRI. Atherosclerosis 222(1):43-49
118. Virmani R, Burke AP, Farb A et al (2006) Pathology of the vulnerable plaque. J Am Coll Cardiol 47(8 Suppl):C13-C18
119. Arbustini E, Dal Bello B, Morbini P et al (1999) Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 82(3):269-272
120. Huang H, Virmani R, Younis H et al (2001) The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 103(8):1051-1056
121. Ehara S, Kobayashi Y, Yoshiyama M et al (2004) Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 110(22):3424-3429
122. Aikawa E, Nahrendorf M, Figueiredo JL et al (2007) Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation 116(24):2841-2850
123. Dunphy MP, Freiman A, Larson SM et al (2005) Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 46 (8):1278-1284
124. Derlin T, Richter U, Bannas P et al (2010) Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med 51 (6):862-865
125. Slobbe LCJ, S.J., Groen J, Poos MJJC, Kommer GJ, Cost of Illness in the Netherlands 2007 : Trends in healthcare expenditure 1999-2010, in RIVM rapport2011, Rijksinstituut voor Volksgezondheid en Milieu RIVM Centraal Bureau voor de Statistiek CBS.
126. Koch-Institut, R. Krankheitskosten. Krankheitskosten [Gesundheitsberichterstattung- Themenhefte] 2009; Available from: http://www.gbe-bund.de/gbe10/ergebnisse.prc-tab?fid012567&suchstring0 &query-id0&sprache0D&fund-typ0TXT&methode0&vt0& verwandte01&page-ret00&seite01&p-lfd-nr042&p-news0&p- sprachkz0D&p-uid0gast&p-aid078162345&hlp-nr02&p-janein0 J#Kap3.1.
127. Taylor MJ, Scuffham PA, McCollam PL et al (2007) Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr Med Res Opin 23(3):495-503
128. Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 125(1):e2-e220
129. Naghavi M, Falk E, Hecht HS et al (2006) From vulnerable plaque to vulnerable patient - part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 98(2A):2H-15H
130. Chan, K.H. and M.K. Ng (2012) Is there a role for coronary angiography in the early detection of the vulnerable plaque? Int J Cardiol (in press)
131. Ait-Oufella H, Kinugawa K, Zoll J et al (2007) Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 115(16):2168-2177
132. Aprahamian T, Rifkin I, Bonegio R et al (2004) Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J Exp Med 199(8):1121-1131